Director/PDMR Shareholding

RNS Number : 4188D

Dechra Pharmaceuticals PLC

16 May 2012

 



Dechra Pharmaceuticals PLC

("the Company")

16 May 2012

Director / PDMR Shareholding

In accordance with DTR 3.1.4R, Dechra Pharmaceuticals PLC announces the following transactions in respect of the Company's ordinary shares of 1 pence each by its Directors and PDMRs.

Under the terms of the Company's Rights Issue announced on 5 April 2012, qualifying shareholders were entitled to purchase 3 New Ordinary Shares in the Company for every 10 Existing Ordinary Shares held on the record date of 23 April 2012, at an issue price of 300 pence per New Ordinary Share.

The Directors and PDMRs (together with their connected persons) acquired the following New Ordinary Shares pursuant to the Rights Issue, which closed for acceptance on 15 May 2012.

Directors and PDMRs	Number of shares acquired pursuant to the Rights Issue	Total number of shares beneficially held following the Rights Issue	% of enlarged issued share capital
Michael Redmond	16,942	73,417	0.08%
Ian Page	101,796	859,751	0.99%
Simon Evans	108,029	1,032,104	1.19%
Ed Torr	60,267	472,767	0.54%
Neil Warner	1,257	5,448	0.01%
Bryan Morton	841	3,645	0.00%
Dr. Chris Richards	1,200	5,200	0.01%
Zoe Goulding	1,289	5,588	0.01%

Options and conditional awards of shares granted under the Dechra Share Options Schemes will be adjusted in accordance with the rules of each scheme to compensate for the effect of the Rights Issue; a further announcement will be made in respect of adjustments made to options and conditional awards held by Executive Directors and PDMRs.

Definitions used in the Prospectus dated 25 April 2012 shall have the same meanings when used in this announcement, unless the context otherwise requires.

For further information

Zoe Goulding, Company Secretary            

Telephone number: 01782 771100

 

END

 

 

RDSBKPDQOBKDQPD